{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:22Z","timestamp":1790969722751,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00198-024-07213-2","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:04:36Z","timestamp":1723050276000},"page":"2225-2230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["One versus 2\u00a0years of alendronate following denosumab: the CARD extension"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8576-3076","authenticated-orcid":false,"given":"Joy N.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z.","family":"Leder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"8","key":"7213_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"11","key":"7213_CR2","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"7213_CR3","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26(12):2773\u20132783","journal-title":"Osteoporos Int"},{"issue":"7","key":"7213_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"7213_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7213_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33(2):190\u2013198","journal-title":"J Bone Miner Res"},{"issue":"11","key":"7213_CR7","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F et al (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37(11):2112\u20132120","journal-title":"J Bone Miner Res"},{"key":"7213_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264\u2013281","journal-title":"J Clin Endocrinol Metab"},{"key":"7213_CR9","unstructured":"Prolia (denosumab) [package insert]. Thousand Oaks, CA: Amgen, Inc; 2024"},{"issue":"2","key":"7213_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","volume":"35","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK et al (2024) The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporos Int 35(2):255\u2013263","journal-title":"Osteoporos Int"},{"issue":"9","key":"7213_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P et al (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728","journal-title":"J Bone Miner Res"},{"issue":"2","key":"7213_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"CH Chesnut 3rd","year":"1995","unstructured":"Chesnut CH 3rd et al (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99(2):144\u2013152","journal-title":"Am J Med"},{"issue":"5","key":"7213_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jbmr.3654","volume":"34","author":"TY Kim","year":"2019","unstructured":"Kim TY et al (2019) Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension i trials. J Bone Miner Res 34(5):810\u2013816","journal-title":"J Bone Miner Res"},{"issue":"3","key":"7213_CR14","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler D et al (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105(3):e255\u2013e264","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"7213_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"Solling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36(7):1245\u20131254","journal-title":"J Bone Miner Res"},{"issue":"12","key":"7213_CR16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD et al (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J Bone Miner Res 34(12):2220\u20132228","journal-title":"J Bone Miner Res"},{"issue":"5","key":"7213_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK et al (2021) Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension. J Bone Miner Res 36(5):921\u2013930","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07213-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:41:30Z","timestamp":1732095690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7213"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07213-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JNT has a financial interest in Amgen. JNT\u2019s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}